CompletedNCT04621851
Retro-prospective Observational Study on Risk of Progression in CP-CML Patients Eligible for TKI Discontinuation
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Milano Bicocca
- Principal Investigator
- Elisabetta Abruzzese, MDOspedale S. Eugenio Roma
- Enrollment
- 260 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2023
Study locations (26)
- McGill University - Jewish General Hospital Division of Hematology and Department of Oncology, Montreal, Quebec, Canada
- Charité University of Berlin - Clinic of Medicine - Hematology and Oncology, Berlin, Germany
- University of Mannheim, Mannheim, Germania, Mannheim, Germany
- ASST-Monza, Monza, Italy/MB, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico UOC di Ematologia, Milan, Italy/Milano, Italy
- Universita di Tor Vergata Ospedale S. Eugenio, Rome, Italy/Rome, Italy
- Istituto di Ematologia "Lorenzo e A. Seragnoli" Policlinico S. Orsola Malpighi,, Bologna, Italy
- CTMO Ematologia Ospedale "Businco", Cagliari, Italy
- Università di Catania Cattedra di Ematologia Ospedale "Ferrarotto", Catania, Italy
- SOC Ematologia Az. Ospedaliera Pugliese Ciaccio (AOPC), Catanzaro, Italy
- Ematologia Ospedale Cuneo, Cuneo, Italy
- UO Ematologia O spedale Milano S. Raffaele, Miano, Italy
- Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli", Naples, Italy
- Azienda Ospedaliera Universitaria Università degli Studi di Napoli "Federico II" Facoltà di Medicina e Chirurgia, Naples, Italy
- U.O. di Ematologia con trapianto A.U. Policlinico "Paolo Giaccone", Palermo, Italy
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04621851 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics